Market Newsdesk

In the news release, Palm Global Partners with Abu Dhabi’s Promax United to Transform Global Finance, Creating the World’s Largest Portfolio of Real-World Asset-Backed Investment Products, Fixed-Income Funds, and Stablecoins, issued 05-May-2025 by Above Food Ingredients Inc. over PR Newswire, we are advised by the company that the first paragraph has been amended, as well as an additional quote and thirteenth and fourteenth paragraph, as originally issued inadvertently. The complete, corrected release follows:

Palm Global Partners with Abu Dhabi’s Promax United to Transform Global Finance, Creating the World’s Largest Portfolio of Real-World Asset-Backed Investment Products, Fixed-Income Funds, and Stablecoins

REGINA, SK
, May 5, 2025 /PRNewswire/ – Above Food Ingredients Inc. (Nasdaq: ABVE) (“Above Food” and the “Company”) has today announced the launch of Palm Promax Investments (“Palm Promax”), a strategic joint venture between Palm Global Technologies (“Palm Global”) and Abu Dhabi conglomerate, Promax United LLC (“Promax”).

Palm Promax seeks to redefine the global financial landscape through the development of next generation investment products and platforms powered by Palm Global’s advanced blockchain, Artificial Intelligence and Web-3 technologies. Its vision is built upon two primary objectives, the creation of the world’s leading digital fixed-income platform and the establishment of the world’s most globally recognized stablecoin digital asset. Both initiatives are anchored by the tokenization of over $1.5 trillion in AA and AAA-rated Real-World Assets and backed by sovereign partnerships in more than fifteen nations.

Underpinned by Promax UAE’s unparalleled access to Real-World Assets and powered by Palm Global’s highly scalable AI driven DeFi ecosystem, Palm Promax has launched with an initial injection of approximately $350 billion in U.S. gold-based assets onto the joint venture’s balance sheet. These assets serve to securitize and anchor its fixed income platform and stablecoin. Through Palm Global’s 30% ownership stake in Palm Promax and its underlying assets, Palm Global will recognize its share of the substantial high-margin revenues, earnings and cash flows generated by the joint venture’s operations.

Promax UAE owns a number of semi-government subsidiary companies, which provide strategic financial access through their direct engagement with central banks globally. This is expected to facilitate the widespread adoption of Palm Promax’s gold-backed stablecoin. With more than fifteen sovereign partnerships already committed to the project, the stablecoin is also designed to address challenges faced by nations whose domestic currencies are not widely accepted for international trade, providing a viable solution to facilitate global commerce.

Chairman of Palm Global, Peter Knez, commented:
 “As the global financial landscape undergoes a seismic shift and the digital world enters a new paradigm, with the United States and other nations introducing regulatory frameworks and strengthening oversight of cryptocurrencies and tokenization, investor confidence in digital assets continues to grow.

Meanwhile, trillions of dollars in private assets, gold, real estate, infrastructure remain trapped in illiquidity, inaccessible to investors and undervalued by markets. With Palm Promax’s unique combination of institutional expertise, highly scalable artificial intelligence and cutting-edge blockchain technologies, we are poised to unlock this vast potential, not merely as participants in the financial transformation but to lead as its architects.

I am thrilled that, through our partnership with Promax UAE, Palm Promax is positioned to become the world’s leading provider of tokenized asset-backed fixed-income funds, stablecoins, and investment platforms. With assets collateralized by gold, AA- and AAA-rated instruments, distinguished by strong histories of positive cash flow, our products and platforms will gain global recognition, enabling us to compete directly with government treasuries and bonds while offering competitive yields. This, I believe, will be truly transformative for the fixed-income investment market and the broader financial sector.

Our distinct advantages have already attracted the support of numerous sovereign wealth funds and central banks, including our esteemed partner, the Central Bank of the UAE. As part of our strategic vision, we are set to launch what we anticipate will be the world’s largest asset-backed stablecoin. This initiative is designed to empower developing economies, including the fifteen African nations we are already working with, by providing a currency that is freely tradable and globally accepted, significantly strengthening their economic standing.

Beyond conventional assets, Palm Promax is pioneering the valuation of nature itself. Carbon credits, biodiversity reserves, AgTech and ecosystem services will soon be integrated into our platform, because true sustainability must align profitability with planetary stewardship. Tokenization is not merely a financial innovation; it is a catalyst for redefining how the world invests in its future.”

His Excellency Louai Mohamed Ali, Group President of Promax United LLC, commented:
 “We are thrilled to partner with Palm Global, bringing together all the essential elements to establish a universally recognized, world-leading fixed-income platform, a ubiquitous digital currency, and an unrivaled position as the global leader in the tokenization of real-world assets.

It has been many years since Peter was at the forefront of the ETF industry at Barclays and BlackRock, helping to shape what is now a $14 trillion market. Today, with Palm Promax, we stand at the precipice of an even greater financial evolution. We are poised to introduce a portfolio of products that will not only surpass this achievement but redefine the investment landscape, with our tokenized, real-world asset-backed funds, products, and stablecoin at its core.

The integration of hundreds of billions of dollars in U.S. and UAE-based assets, with plans to expand to over $1.5 trillion, combined with Palm Global’s cutting-edge technology and exceptional leadership team, led by Peter, presents an extraordinary opportunity. This initiative will not only propel Palm Promax to the forefront of the financial industry but also solidify Abu Dhabi’s position as one of the world’s most influential financial hubs.”

Lionel Kambeitz, Chairman and CEO of Above Food Ingredients commented: “We were proud to witness and be part of this launch last week in Abu Dhabi in the presence of very esteemed company. There is no doubt that Above Food’s acquisition of Palm Global will significantly enhance shareholder value.

We are very excited about the magnitude of this deal and its contribution to our balance sheet, and what this clearly means to the future of the company. We are very much looking forward to working with our new partners on this transformational journey, and for the benefit of all our shareholders.

About Above Food

Above Food Corp. is a differentiated, regenerative ingredient company that produces products made with real nutritious, flavorful ingredients and delivered with transparency. Above Food’s vision is to create a sustainable healthier world — one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, Above Food delivers nutritious food ingredients to businesses and consumers with traceability and sustainability.

About Promax United Investments and Preferred Partners

Promax United Investments with extensive global network of government, semi-government, and institutional partnerships unlocking access to high-value strategic assets and advanced infrastructure technologies. Spearheads the digital transformation in finance, offering comprehensive solutions, a diverse investment portfolio, and strategic partnerships that promote collaboration and mutual success. It’s strategic positioning aligns with Abu Dhabi Economic Vision 2030, placing the United Arab Emirates at the forefront of evolving market dynamics and progressive industry trends. Promax creates a sustainable business model that prioritize both financial success and social impact, paving the way for a future where profit and purpose harmoniously drive positive change. Promax United website is available at:www.promaxunited.com

About Palm Global

Palm Global is a next-generation innovator in digital financial products and platforms, asset tokenization, super-apps, AgTech, and sustainability, operating out of San Francisco, Dubai, Hong Kong, and Singapore. Utilizing AI, blockchain, and decentralized finance (DeFi) technologies, Palm Global delivers highly scalable solutions that drive economic empowerment and financial inclusion for all.

As part of its offering, Palm Global’s AgTech division serves millions of farmers across Africa, Southeast Asia, and the Americas, facilitating access to credit, insurance, and advanced agricultural technologies through its platforms and super-apps, driving sustainable growth and food security at scale.

Through strategic partnerships with governments, global institutions, and NGOs, Palm Global is accelerating the adoption of digital solutions that transform global agriculture and strengthen financial resilience in underserved markets. The Palm Global website is available at www.palmglobal.ai

Cautionary Statements

This press release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively “forward-looking information“), which are based on Above Food’s and Palm Global’s current internal expectations, estimates, projections, assumptions and beliefs. The use of any of the words “believe”, “estimate”, “anticipate”, “expect”, “plan”, “predict”, “outlook”, “target”, “project”, “plan”, “may”, “could”, “will”, “shall”, “should”, “intend”, “potential”, “seek”, “future”, “outlook” and similar expressions that predict or indicate future events or trends or events that are not statements of historical matters are intended to identify forward-looking information. Forward-looking information in this press release includes, but is not limited to: statements regarding the anticipated benefits of the acquisition, particularly that the acquisition will offer certain advantages to Above Food’s shareholders and its business as a whole; the expectation that following completion of the acquisition, the Above Food’s shareholders and Palm Global’s shareholders will continue to participate in the upside of the combined company; and statements regarding estimates and forecasts of financial and performance metrics and projections of market opportunity. Forward-looking information is not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Above Food and Palm Global currently believe the expectations reflected in the forward-looking information in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct, and readers should not place undue reliance on such forward-looking information. The forward-looking information in this press release is subject to a number of known and unknown risks and uncertainties that could cause actual events or results to differ materially, including, but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions; (ii) the expected benefits of the acquisition are not obtained; (iii) the ability to meet stock exchange listing standards following the consummation of the acquisition; (v) the risk that the acquisition disrupts current plans and operations of Above Food as a result of the consummation of the acquisition; (vi) failure to realize the anticipated benefits of the acquisition, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (vii) costs related to the acquisition; (viii) changes in applicable law or regulations; (ix) risks relating to the stewardship of Above Food by a newly appointed chairman and CEO; * the outcome of any legal proceedings that may be instituted against Palm Global or Above Food; (xi) the effects of competition on Above Food’s future business; (xii) the ability of Palm Global or the combined company to issue equity or equity-linked securities or obtain debt financing; (xiii) the enforceability of Above Food’s intellectual property rights, including its copyrights, patents, trademarks and trade secrets, and the potential infringement on the intellectual property rights of others; and (xiv) Above Food’s ability to execute its planned acquisition strategy, including to successfully integrate completed acquisitions and realize anticipated synergies. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking information. There may be additional risks that Above Food does not presently know or that Above Food currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking information.

In addition, forward-looking information reflects Above Food’s expectations, plans or forecasts of future events and views as of the date of this press release. Above Food anticipates that subsequent events and developments may cause Above Food’s assessments to change. However, while Above Food may elect to update the forward-looking information at some point in the future, Above Food specifically disclaims any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Nothing in this press release should be regarded as a representation by any person that the forward-looking information set forth herein will be achieved or that any of the contemplated results of such forward-looking information will be achieved. Accordingly, undue reliance should not be placed upon the forward-looking information. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement.

Additional Information and Where to Find It:

INVESTORS AND SECURITY HOLDERS OF ABOVE FOOD ARE URGED TO READ THE DOCUMENTS FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ABOVE FOOD. Investors and security holders will be able to obtain free copies of the documents filed with the SEC by Above Food through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Above Food will also be available free of charge on Above Food’s website at https://abovefood.com or by contacting Above Food’s Investor Relations Department at 2305 Victoria Ave #001, Regina, Saskatchewan, Canada, S4P 0S7.

View original content to download multimedia:https://www.prnewswire.com/news-releases/palm-global-partners-with-abu-dhabis-promax-united-to-transform-global-finance-creating-the-worlds-largest-portfolio-of-real-world-asset-backed-investment-products-fixed-income-funds-and-stablecoins-302447256.html

SOURCE Above Food Ingredients Inc.

NEW YORK
, May 6, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on May 6th

• Stocks are looking at fractional losses early Tuesday as the Federal Reserve begins its two-day policy meeting. Markets anticipate that the central bank will keep rates steady when it delivers its decision.
• Treasury Secretary Scott Bessent told CNBC Monday that the U.S. is very close to new trade deals. According to Bloomberg, India has proposed zero tariffs on certain goods.
• Semiconductors, advanced-micro devices, and super-microcomputer, once high-flying portions of the market, will report earnings after the close.

Opening Bell

UConn Women’s Basketball celebrates their 12^th National Championship

Closing Bell

Ametek Inc. (NYSE: AME) celebrates its 95th anniversary as a public company

Watch NYSE TV Live every weekday 9:00-10:00am ET

View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-content-advisory-pre-market-update–federal-reserve-begins-two-day-policy-meeting-302447225.html

SOURCE New York Stock Exchange

COLUMBUS, Ga.
, May 6, 2025 /PRNewswire/ — Aflac, a leading provider of health supplemental insurance in the U.S., is expanding its partnership with Empathy, an innovative technology company that provides compassionate, on-demand support to families in life’s most challenging moments, from dealing with the loss of a loved one to planning for their future. Effective July 1, Empathy LifeVault™ will be available at no additional cost to some new and existing group term life insurance certificate holders covered by Aflac.

LifeVault is an intuitive, secure, legally compliant digital platform for legacy planning. It streamlines the creation and management of essential documents, complementing Aflac customers’ life insurance policies. By simplifying the process, LifeVault makes legacy planning more accessible, ensuring members can confidently safeguard their health care, finances and wishes. These services align with Aflac’s commitment to provide comprehensive care and value to its customers.

The expanded partnership complements Empathy’s loss support service, initially introduced to Aflac customers in July 2024, as part of the life insurance benefits Aflac provides to beneficiaries and members upon the death of a loved one.

LifeVault is an online platform that supports the creation of a comprehensive end-of-life plan so members can better protect their families. Included with LifeVault is:

• Last will and testament: Ensuring that wishes are honored and loved ones are protected. A will and testament can often be created in under 15 minutes.
• Advance health care directive: Assistance in communicating medical wishes and help for loved ones in make challenging decisions.
• Power of attorney: Granting legal authority to a trusted loved one to act on their behalf.
• Funeral directive: Compiling preferences for a funeral to help ease the burden on family members by preventing them from having to make challenging decisions.

Together, these two offerings help families navigate loss and plan for the future, enhancing Aflac’s commitment to help ease burdens and empower families through life’s most challenging moments.

“The time to plan for inevitabilities in life is before they happen, and that includes the final wishes of individuals facing end of life challenges. End of life is a reality that people are often uncomfortable discussing, which is why Aflac wants to help ease and dignify this process,” said Aflac Senior Vice President, Life, Absence and Disability Solutions, Scott A. Beeman. “We believe adding LifeVault to our portfolio, which provides grief support and enables members to plan for the future with greater confidence so that families will be better protected financially and emotionally, will help provide peace of mind for our members and their families when a loved one has passed.”

“From day one, Empathy was built to work hand in hand with financial institutions and life insurance carriers, as a trusted partner that helps these industries evolve to better serve families during their time of need,” said Ron Gura, Co-Founder and CEO of Empathy. “We believe that the most meaningful way to transform how people prepare for and experience loss is by embedding compassionate, intuitive technology within the institutions they already rely on. Aflac’s decision to partner with Empathy, and now to integrate LifeVault, underscores the success of this vision, expanding access while reinforcing the critical role insurers and financial institutions play in shaping a more prepared, supported future for families everywhere.”

For more information, visit https://www.aflac.com/brokers/products/group-life-insurance.aspx.

ABOUT AFLAC INCORPORATED

Aflac Incorporated (NYSE: AFL), a Fortune 500 company, has helped provide financial protection and peace of mind for nearly seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan. In the U.S., Aflac is the No. 1 provider of supplemental health insurance products.¹ In Japan, Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force. The company takes pride in being there for its policyholders when they need us most, as well as being included in the World’s Most Ethical Companies by Ethisphere for 19 consecutive years (2025) and Fortune’s World’s Most Admired Companies for 24 years (2025). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been included in the Dow Jones Sustainability North America Index (2024) for 11 years. To find out how to get help with expenses health insurance doesn’t cover, get to know us at aflac.com or aflac.com/español. Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at investors.aflac.com under “Sustainability.”

¹ LIMRA 2023 U.S. Supplemental Health Insurance Total Market Report 

ABOUT EMPATHY

Empathy is a leading technology company transforming the way people plan for and navigate life’s toughest moments. Serving over 40 million people across North America, Empathy currently partners with seven of the top ten U.S. life insurance carriers and handles one in five life insurance claims nationwide. With $90 million in funding from top-tier venture firms including Index Ventures and General Catalyst, as well as strategic investment from global insurance leaders including Allianz, MassMutual, MetLife, New York Life, Securian, and Sumitomo, Empathy combines cutting-edge innovation with compassion to provide unparalleled support for bereavement, estate management, legacy planning, and more. Recognized by Apple, Google Play, and Fast Company, Empathy is setting the standard for modern family care and workplace benefits. Learn more at www.empathy.com.

Group life, disability and absence services are provided by Continental American Insurance Company (CAIC); in New York, products and services are provided by American Family Life Assurance Company of New York; in California, coverage is offered by Continental American Life Insurance Company. Products may not be available in all states and may vary depending on state law. These services are intended for general purposes and are not a substitute for professional psychological or medical advice. Empathy may not be available in some states in connection with this partnership. CAIC’s affiliation with the Value-Added Service providers is limited only to a marketing alliance, and CAIC and the Value-Added Service providers are not under any sort of mutual ownership, joint venture, or are otherwise related. CAIC makes no representations or warranties regarding the Value-Added Service providers and does not own or administer any of the products or services provided by the Value-Added Service providers. Each Value-Added Service provider offers its products and services subject to its own terms, limitations and exclusions. Value-Added Services are not available in Idaho, Minnesota or New Mexico. State availability may vary. Continental American Insurance Company, a proud member of the Aflac family of insurers, is a wholly-owned subsidiary of Aflac Incorporated.

Media contact:
Jon Sullivan, 706-763-4813 or [email protected]
Media contact: Estela Weinmann, [email protected]

Analyst and investor contact:
David A. Young, 706-596-3264, 800-235-2667 or [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/aflac-expands-partnership-with-empathy-to-offer-enhanced-legacy-planning-services-with-lifevault-302447254.html

SOURCE Aflac

–       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy

–       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy

–       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents

NEW YORK
, May 6, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioning agent intended to replace non-targeted chemotherapeutic conditioning agents such as Fludarabine and Cyclophosphamide (Flu/Cy) to address serious CAR-T related toxicities including immune effector cell-associated neurotoxicity (ICANS) and cytokine release syndrome (CRS), to potentially improve patient access and outcomes. Currently, there are seven CAR-T therapies approved for certain leukemias and lymphomas and multiple myeloma, that over 150,000 patients are diagnosed with annually.  In 2024, the seven approved CAR-T therapies generated over $4 billion in sales and CAR-T therapies are forecasted to reach $12 billion in annual sales in 2030.

Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at UTSW said, “We are thrilled to initiate patient enrollment to study Iomab-ACT targeted radiotherapy conditioning with a commercial CAR-T therapy. Iomab-ACT is supported by compelling preclinical and clinical data, and we believe it has immense potential to eliminate the need for chemotherapy-based conditioning, which is a major barrier for many patients seeking CAR-T treatment. Despite the positive impact CAR-T therapy has had on patient outcomes, there is still significant room for improvement. We are optimistic that Iomab-ACT can transform CAR-T therapy conditioning if this trial demonstrates it has the ability to increase patients access and reduce the rates and severity of ICANS and CRS and also potentially improve patient outcomes. We are excited to begin treating patients with Iomab-ACT and eager to present our preliminary findings later this year.”

Iomab-ACT targets CD45, a cell surface marker expressed on immune cells relevant to CAR-T therapy including lymphocytes and is the only clinical stage conditioning agent targeting CD45. Preclinical data demonstrated that Iomab-ACT can selectively target immune cells implicated in CAR-T toxicities, while sparing bone marrow stem cells, red blood cells and platelets. Preclinical and clinical data also showed that Iomab-ACT produces transient lymphodepletion that aligns with the CAR-T treatment process. This data supported the first clinical trial of Iomab-ACT with a novel CD19 CAR-T therapy in collaboration with Memorial Sloan Kettering Cancer Center (MSK) in patients heavily pretreated with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) or Diffuse Large B-cell Lymphoma (DLBCL). In this study, no patients (0/4) developed ICANS of any grade, and minimal CRS. Iomab-ACT also demonstrated transient depletion of peripheral blood lymphocytes and monocytes, persistence of CAR T-cells up to 8 weeks and minimal non-hematologic toxicities. These positive findings supported the continued advancement of Iomab-ACT and the initiation of the commercial CAR-T trial at UTSW.

Sandesh Seth, Actinium’s Chairman and CEO, stated, “This is a pivotal moment for our Iomab-ACT CD45 targeted radiotherapy conditioning program. Iomab-ACT is a highly differentiated conditioning agent that has produced promising initial clinical results where multiple targeted conditioning approaches including monoclonal antibodies and antibody drug conjugates directed against a variety of targets have not achieved clinical success to date. Based on the promising initial outcomes from the pilot study of Iomab-ACT  with a novel CD19 CAR-T, we are incredibly excited by the potential of this commercial CAR-T trial and future development path. With initial clinical data expected beginning in the second half of this year, we are making strong progress to achieving our goal of establishing Iomab-ACT as a universal targeted conditioning regimen for CAR-T and other cellular therapies.”

Targeted Radiotherapy CAR-T Conditioning Opportunity

A multi-billion-dollar market opportunity exists for better conditioning in other areas of cellular therapy, such as CAR-T. Currently, there are seven CAR T-cell therapies targeting CD19 for lymphoma and leukemia and BCMA for multiple myeloma that are approved by the FDA with total sales of over $4.0 billion in 2024. The pipeline of CAR-T therapies in development has rapidly expanded, with the addressable patient population expected to nearly double and reach approximately 93,000 patients in the U.S. by 2030 based on the current pipeline of cellular therapies. The addressable market for Iomab-ACT is in line with the patient population for cellular therapies that is approximately150,000 patients annually across the indications in which CAR-T therapies are approved, as all patients receive conditioning of some type. We believe a potential blockbuster revenue opportunity exists for Iomab-ACT assuming it can provide clinical benefits related to adverse events related to CAR-T, longer duration of response or improved survival outcomes.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA^® and OPDIVO^® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. ATNM-400 is Actinium’s novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data demonstrating higher efficacy than Pluvicto (PSMA-617-Lutetium-177) and potent efficacy in Pluvicto resistant prostate cancer models. Iomab-ACT, Actinium’s next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company’s R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-announces-enrollment-of-first-patient-in-the-iomab-act-commercial-car-t-trial-at-the-university-of-texas-southwestern-medical-center-302446586.html

SOURCE Actinium Pharmaceuticals, Inc.